Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

Clinical trial NCT05467943 · COMPLETED

Trial details

NCT number: NCT05467943
Sponsor: Hutchmed
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory Follicular Lymphoma With EZH2

Start date: 2022-07-29
Primary completion: 2024-11-30
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.